You need to login...
If you are not registered...
| Subscribe to Templeton Apus - Universal: | For a free, non-obligation trial: |
|
or call us on: +44 (0)20 7769 6707 or email: apus@templetonapus.com |
|
Most viewed
- 1. Livent CEO to EV industry: sign better deals or risk lithium supply
- 2. Versant debuts Matterhorn Biosciences with $30M to create better TCR treatments
- 3. Dyuthi Bioscience with HCG embarks on human studies at 3 hospitals for a repurposed herbal drug for COVID-19 patients
- 4. Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations
- 5. New biotech startup GentiBio lands $20M, inks licensing deals with Seattle Children's and BRI
- 6. Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors
- 7. Daiichi Sankyo and AstraZeneca to Jointly Evaluate Treatment Combination for EGFR-Mutated NSCLC
- 8. Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
- 9. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- 10. FDA expands approval for clonoSEQ assay to detect MRD in CLL patients
Last updated at 23:02 GMT
Sectors & Industries
© Copyright 2020 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK